≥99% β-NMN purity
Purity is verified by HPLC (high-performance liquid chromatography).
Current Foundation Product
Human NMN research. Your use documented over 100 days.
Research has reported age-associated declines in NAD⁺ levels in certain tissues and biological contexts. Controlled human studies have examined NMN in relation to circulating NAD⁺ and selected measures of physical function, sleep, muscle metabolism, and exercise physiology.
Ultra Pure™ NMN is the current Foundation Product used during RL100's structured 100-day documentation window.
This page explains the current Foundation Product used within RL100. It does not provide standalone NMN checkout.
What human studies have reported
Research relevant to physical function, sleep, metabolism, and cellular NAD⁺.
NMN and the NAD⁺ pathway. NAD⁺ participates in cellular energy transfer, redox reactions, metabolic signaling, DNA-repair activity, and other cellular processes. NMN is a naturally occurring precursor the body can use in NAD⁺ biosynthesis. This defined relationship is one reason NMN has been examined in controlled human research.
Ingredientβ-nicotinamide mononucleotide
PathwayDirect precursor in NAD⁺ biosynthesis
Human findingRepeated increases in circulating NAD⁺-related measures
The findings below are drawn from the broader human NMN literature. Each finding reflects a defined population, dose, duration, and study material. Full study records are maintained in the HealthspanX Evidence Center.
No featured papers are currently configured for this page. Add papers to the Featured papers metafield to populate this section.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Product controls
Verified product credentials.
These are the credentials HealthspanX maintains for Ultra Pure™ NMN as the current Foundation Product.
Third-party test report per batch
A third-party test report is available for each batch.
NSF-certified cGMP facility
Manufactured in an NSF-certified cGMP facility.
R
HealthspanX Evidence Center
Review full study analyses, trial populations, doses, endpoints, limitations, and disclosures.
Review Human NMN ResearchT
Quality and testing
Review the available analytical and quality information for the current Foundation Product.
Review Quality InformationThe RL100 documentation window
Research describes study groups. RL100 documents the participant's own window.
Human research cannot predict what one person will observe. During RL100, the current Foundation Protocol is kept consistent while the same 12 biological areas are documented at Day 0, Day 30, and Day 100.
DAY 0
Official baseline
Completed before the first dose and then locked for the window.
DAY 30
Early capture
The same biological areas are recorded again under the ongoing protocol.
DAY 100
Completion
The Outcome Report compares Day 100 with the locked Day 0 baseline. Vitality Delta™ is reported here only.
Common questions
What to know before starting RL100.
Can I buy Ultra Pure™ NMN by itself on this page?
No. This public page explains the current Foundation Product used within RL100. It routes visitors to RL100 or the optional Radiant Life™ Assessment and does not provide standalone NMN checkout.
Why is NMN the current Foundation Product?
Its defined relationship to the NAD⁺ pathway, published human research, and fit for consistent use make it suitable for RL100's standardized documentation window.
How is dosage determined during RL100?
Dosage is age-guided and locked at Day 0 for the full 100-day window. It is not adjusted during the window.
Is the Radiant Life™ Assessment required before starting RL100?
No. The Assessment is an optional starting snapshot. Both the direct route and the Assessment-First route converge on the same RL100 lifecycle, with Day 0 establishing the mandatory official baseline.
Connect human NMN research with a structured record of your own use.
Start RL100 directly, review the research, or begin with the optional Radiant Life™ Assessment.